Cargando…

AS-605240 Blunts Osteoporosis by Inhibition of Bone Resorption

BACKGROUND: Osteoporosis is a metabolic bone disease. Osteoclasts are significantly involved in the pathogenesis of osteoporosis. AS-605240 (AS) is a small molecule PI3K-γ inhibitor and is less toxic compared to pan-PI3K inhibitors. AS also exerts multiple biological effects including anti-inflammat...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Jiacheng, Cai, Guoping, Shen, Jinlong, Cheng, Pu, Zhang, Jiapeng, Jiang, Dengteng, Xu, Xianquan, Lu, Fangying, Chen, Lihua, Chen, Haixiao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10150757/
https://www.ncbi.nlm.nih.gov/pubmed/37138583
http://dx.doi.org/10.2147/DDDT.S403231
_version_ 1785035415268360192
author Sun, Jiacheng
Cai, Guoping
Shen, Jinlong
Cheng, Pu
Zhang, Jiapeng
Jiang, Dengteng
Xu, Xianquan
Lu, Fangying
Chen, Lihua
Chen, Haixiao
author_facet Sun, Jiacheng
Cai, Guoping
Shen, Jinlong
Cheng, Pu
Zhang, Jiapeng
Jiang, Dengteng
Xu, Xianquan
Lu, Fangying
Chen, Lihua
Chen, Haixiao
author_sort Sun, Jiacheng
collection PubMed
description BACKGROUND: Osteoporosis is a metabolic bone disease. Osteoclasts are significantly involved in the pathogenesis of osteoporosis. AS-605240 (AS) is a small molecule PI3K-γ inhibitor and is less toxic compared to pan-PI3K inhibitors. AS also exerts multiple biological effects including anti-inflammatory, anti-tumor, and myocardial remodeling promotion. However, the involvement of AS in the differentiation and functions of osteoclasts and the effect of AS in treating patients with osteoporosis is still unclear. PURPOSE: This study aimed to investigate if AS inhibits the differentiation of osteoclasts and resorption of the bones induced by M-CSF and RANKL. Next, we evaluated the therapeutic effects of AS on bone loss in ovariectomy (OVX)-induced osteoporosis mice models. METHODS: We stimulated bone marrow-derived macrophages with an osteoclast differentiation medium containing different AS concentrations for 6 days or 5μM AS at different times. Next, we performed tartrate-resistant acid phosphatase (TRAP) staining, bone resorption assay, F-actin ring fluorescence, real-time quantitative polymerase chain reaction (RT-qPCR), and Western blotting (WB). Next, MC3T3-E1s (pre-osteoblast cells) were differentiated to osteoblast by stimulating the cells with varying AS concentrations. Next, we performed alkaline phosphatase (ALP) staining, RT-qPCR, and WB on these cells. We established an OVX-induced osteoporosis mice model and treated the mice with 20mg/kg of AS. Finally, we extracted the femurs and performed micro-CT scanning, H&E, and TRAP staining. RESULTS: AS inhibits the formation of osteoclasts and resorption of bone triggered by RANKL by inhibiting the PI3K/Akt signaling pathway. Furthermore, AS enhances the differentiation of osteoblasts and inhibits bone loss due to OVX in vivo. CONCLUSION: AS inhibits osteoclast production and enhances osteoblast differentiation in mice, thus providing a new therapeutic approach for treating patients with osteoporosis.
format Online
Article
Text
id pubmed-10150757
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-101507572023-05-02 AS-605240 Blunts Osteoporosis by Inhibition of Bone Resorption Sun, Jiacheng Cai, Guoping Shen, Jinlong Cheng, Pu Zhang, Jiapeng Jiang, Dengteng Xu, Xianquan Lu, Fangying Chen, Lihua Chen, Haixiao Drug Des Devel Ther Original Research BACKGROUND: Osteoporosis is a metabolic bone disease. Osteoclasts are significantly involved in the pathogenesis of osteoporosis. AS-605240 (AS) is a small molecule PI3K-γ inhibitor and is less toxic compared to pan-PI3K inhibitors. AS also exerts multiple biological effects including anti-inflammatory, anti-tumor, and myocardial remodeling promotion. However, the involvement of AS in the differentiation and functions of osteoclasts and the effect of AS in treating patients with osteoporosis is still unclear. PURPOSE: This study aimed to investigate if AS inhibits the differentiation of osteoclasts and resorption of the bones induced by M-CSF and RANKL. Next, we evaluated the therapeutic effects of AS on bone loss in ovariectomy (OVX)-induced osteoporosis mice models. METHODS: We stimulated bone marrow-derived macrophages with an osteoclast differentiation medium containing different AS concentrations for 6 days or 5μM AS at different times. Next, we performed tartrate-resistant acid phosphatase (TRAP) staining, bone resorption assay, F-actin ring fluorescence, real-time quantitative polymerase chain reaction (RT-qPCR), and Western blotting (WB). Next, MC3T3-E1s (pre-osteoblast cells) were differentiated to osteoblast by stimulating the cells with varying AS concentrations. Next, we performed alkaline phosphatase (ALP) staining, RT-qPCR, and WB on these cells. We established an OVX-induced osteoporosis mice model and treated the mice with 20mg/kg of AS. Finally, we extracted the femurs and performed micro-CT scanning, H&E, and TRAP staining. RESULTS: AS inhibits the formation of osteoclasts and resorption of bone triggered by RANKL by inhibiting the PI3K/Akt signaling pathway. Furthermore, AS enhances the differentiation of osteoblasts and inhibits bone loss due to OVX in vivo. CONCLUSION: AS inhibits osteoclast production and enhances osteoblast differentiation in mice, thus providing a new therapeutic approach for treating patients with osteoporosis. Dove 2023-04-27 /pmc/articles/PMC10150757/ /pubmed/37138583 http://dx.doi.org/10.2147/DDDT.S403231 Text en © 2023 Sun et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Sun, Jiacheng
Cai, Guoping
Shen, Jinlong
Cheng, Pu
Zhang, Jiapeng
Jiang, Dengteng
Xu, Xianquan
Lu, Fangying
Chen, Lihua
Chen, Haixiao
AS-605240 Blunts Osteoporosis by Inhibition of Bone Resorption
title AS-605240 Blunts Osteoporosis by Inhibition of Bone Resorption
title_full AS-605240 Blunts Osteoporosis by Inhibition of Bone Resorption
title_fullStr AS-605240 Blunts Osteoporosis by Inhibition of Bone Resorption
title_full_unstemmed AS-605240 Blunts Osteoporosis by Inhibition of Bone Resorption
title_short AS-605240 Blunts Osteoporosis by Inhibition of Bone Resorption
title_sort as-605240 blunts osteoporosis by inhibition of bone resorption
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10150757/
https://www.ncbi.nlm.nih.gov/pubmed/37138583
http://dx.doi.org/10.2147/DDDT.S403231
work_keys_str_mv AT sunjiacheng as605240bluntsosteoporosisbyinhibitionofboneresorption
AT caiguoping as605240bluntsosteoporosisbyinhibitionofboneresorption
AT shenjinlong as605240bluntsosteoporosisbyinhibitionofboneresorption
AT chengpu as605240bluntsosteoporosisbyinhibitionofboneresorption
AT zhangjiapeng as605240bluntsosteoporosisbyinhibitionofboneresorption
AT jiangdengteng as605240bluntsosteoporosisbyinhibitionofboneresorption
AT xuxianquan as605240bluntsosteoporosisbyinhibitionofboneresorption
AT lufangying as605240bluntsosteoporosisbyinhibitionofboneresorption
AT chenlihua as605240bluntsosteoporosisbyinhibitionofboneresorption
AT chenhaixiao as605240bluntsosteoporosisbyinhibitionofboneresorption